Disease Areas:
Cough,Idiopathic pulmonary fibrosisDevice Types:
VitaloJAKThis was a single-center, randomized, double-blind crossover study that examined the efficacy of a single inhaled dose of VRP700 versus placebo for reducing cough frequency in 20 patients with IPF with chronic cough. The primary endpoint was the number of coughs in the 4-hour period following the end of nebulized treatment, measured using the Vitalograph VitaloJAK device.